S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
S&P 500   5,248.49
DOW   39,760.08
QQQ   444.83
Stock market today: World shares are mostly higher after S&P 500 sets another record
5 Dividend Kings Stocks to Load Up on Now
Palantir Technologies: Bearish Sentiment, Bullish Chart Signals
Chinese leader Xi issues a positive message at a meeting with US business leaders as ties improve
Mid-Cap Stocks to Outperform the Market This Cycle
Is DraftKings A Good Bet Ahead of Q1 Earnings?
Low VIX? 3 High Beta Stocks To Boost Your Returns
NASDAQ:FIXX

Homology Medicines (FIXX) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
$0.29
$0.93
52-Week Range
N/A
Volume
401,467 shs
Average Volume
249,289 shs
Market Capitalization
$54.33 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.13

Homology Medicines MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
∞ Upside
$2.13 Price Target
Short Interest
Healthy
0.81% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.33
Upright™ Environmental Score
News Sentiment
0.47mentions of Homology Medicines in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$11,581 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.75) to ($0.70) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.22 out of 5 stars

Medical Sector

165th out of 939 stocks

Pharmaceutical Preparations Industry

64th out of 431 stocks

FIXX stock logo

About Homology Medicines Stock (NASDAQ:FIXX)

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

FIXX Stock News Headlines

FIXX Homology Medicines, Inc.
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Homology Medicines Inc (FIXX)
4x Better than Bitcoin
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Q32 Bio and Homology Medicines Announce Merger Agreement
See More Headlines
Receive FIXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Homology Medicines and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/27/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:FIXX
Fax
N/A
Employees
7
Year Founded
2015

Price Target and Rating

Average Stock Price Target
$2.13
High Stock Price Target
$3.50
Low Stock Price Target
$0.75
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-112,960,000.00
Net Margins
-4,779.31%
Pretax Margin
-7,532.87%

Debt

Sales & Book Value

Annual Sales
$1.16 million
Book Value
$1.26 per share

Miscellaneous

Free Float
48,774,000
Market Cap
$54.33 million
Optionable
Optionable
Beta
-0.10

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

FIXX Stock Analysis - Frequently Asked Questions

Should I buy or sell Homology Medicines stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Homology Medicines in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FIXX shares.
View FIXX analyst ratings
or view top-rated stocks.

What is Homology Medicines' stock price target for 2024?

2 equities research analysts have issued 1 year target prices for Homology Medicines' stock. Their FIXX share price targets range from $0.75 to $3.50. On average, they anticipate the company's share price to reach $2.13 in the next year.
View analysts price targets for FIXX
or view top-rated stocks among Wall Street analysts.

When is Homology Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our FIXX earnings forecast
.

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The company had revenue of $1.68 million for the quarter, compared to analysts' expectations of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%.

When did Homology Medicines' stock split?

Shares of Homology Medicines split on the morning of Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly minted shares were payable to shareholders after the market closes on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Homology Medicines investors own include Editas Medicine (EDIT), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Gossamer Bio (GOSS), Spero Therapeutics (SPRO), Alector (ALEC), Dynavax Technologies (DVAX), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO).

When did Homology Medicines IPO?

Homology Medicines (FIXX) raised $100 million in an initial public offering on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI acted as the underwriters for the IPO and BTIG was co-manager.

Who are Homology Medicines' major shareholders?

Homology Medicines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (3.36%), Vanguard Group Inc. (3.36%), Newtyn Management LLC (2.42%), BML Capital Management LLC (1.29%), George Kaiser Family Foundation (0.53%) and ADAR1 Capital Management LLC (0.51%). Insiders that own company stock include Albert Seymour, Arthur Tzianabos, Julie Jordan, Michael Lee Blum, Paul Alloway, Timothy P Kelly and W Bradford Smith.
View institutional ownership trends
.

How do I buy shares of Homology Medicines?

Shares of FIXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FIXX) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners